Molecular response and clinical outcome
| Patient no. . | BCR-ABL day 28 . | Maximum response . | Relapse . | Intervention . | BCR-ABL at last follow-up . | Follow-up, mo . |
|---|---|---|---|---|---|---|
| Specific cytotoxicity in vitro/pentamer in vivo positive | ||||||
| 1 | 0.1 | MMR | Cyt +250 | IM, DLI | ND | 63 |
| 3 | 0.07 | PCR-negative | — | — | ND | 55 |
| 5 | ND | PCR-negative | — | — | ND | 51 |
| 11 | ND | PCR-negative | — | — | ND | 41 |
| 14 | 0.12 | PCR-negative | — | — | ND | 31 |
| Specific cytotoxicity in vitro/pentamer in vivo-negative | ||||||
| 6 | 0.003 | PCR-negative | Mol +630 | DLI, IM | 0.08 | 47 cGvHD |
| 12 | ND | MMR | — | — | 0.03 | 40 |
| Cytotoxicity-negative/pentamer in vivo-negative | ||||||
| 2 | 0.15 | PCR-negative | Mol +320 | DLI, IM | 0.1 | 60 cGvHD |
| Cytoxoxicity-negative/pentamer in vivo-positive | ||||||
| 4 | 0.34 | MMR | Hem +330 | IM, DLI | ND | 53 cGvHD |
| 7 | 0.07 | PCR-negative | Mol +270 | — | 0.12 | 45 |
| 8 | ND | PCR-negative | Mol +420 | IM | 0.05 | 44 cGvHD |
| 9 | ND | PCR-negative | — | — | ND | 42 |
| 12* | ND | MMR | — | — | 0.03 | 40 |
| 13 | ND | PCR-negative | — | — | ND | 39 |
| Early death | ||||||
| 10 | ND | PCR-negative | — | — | ND | 4† |
| Patient no. . | BCR-ABL day 28 . | Maximum response . | Relapse . | Intervention . | BCR-ABL at last follow-up . | Follow-up, mo . |
|---|---|---|---|---|---|---|
| Specific cytotoxicity in vitro/pentamer in vivo positive | ||||||
| 1 | 0.1 | MMR | Cyt +250 | IM, DLI | ND | 63 |
| 3 | 0.07 | PCR-negative | — | — | ND | 55 |
| 5 | ND | PCR-negative | — | — | ND | 51 |
| 11 | ND | PCR-negative | — | — | ND | 41 |
| 14 | 0.12 | PCR-negative | — | — | ND | 31 |
| Specific cytotoxicity in vitro/pentamer in vivo-negative | ||||||
| 6 | 0.003 | PCR-negative | Mol +630 | DLI, IM | 0.08 | 47 cGvHD |
| 12 | ND | MMR | — | — | 0.03 | 40 |
| Cytotoxicity-negative/pentamer in vivo-negative | ||||||
| 2 | 0.15 | PCR-negative | Mol +320 | DLI, IM | 0.1 | 60 cGvHD |
| Cytoxoxicity-negative/pentamer in vivo-positive | ||||||
| 4 | 0.34 | MMR | Hem +330 | IM, DLI | ND | 53 cGvHD |
| 7 | 0.07 | PCR-negative | Mol +270 | — | 0.12 | 45 |
| 8 | ND | PCR-negative | Mol +420 | IM | 0.05 | 44 cGvHD |
| 9 | ND | PCR-negative | — | — | ND | 42 |
| 12* | ND | MMR | — | — | 0.03 | 40 |
| 13 | ND | PCR-negative | — | — | ND | 39 |
| Early death | ||||||
| 10 | ND | PCR-negative | — | — | ND | 4† |
MMR indicates major molecular response (< 0.1); Cyt, cytogenetic relapse; Mol, molecular relapse; Hem, cGvHD, chronic GVHD; CNS, central nervous system; ND, not detectable (below the detection limit of the nested PCR assay, < 1-2 × 10−6); and —, not applicable.